We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Direct Mailing Improves Screening for Colorectal Cancer

By LabMedica International staff writers
Posted on 26 Sep 2012
Direct mailing of fecal occult blood test (FOBT) kits to patients eligible for colorectal cancer screening appears to be efficacious for improving screening.

Appropriate screening and early detection can greatly reduce colorectal cancer, associated morbidity and mortality, and several national guidelines recommend regular screening for colorectal cancer among adults aged 50 years and older with high-sensitivity FOBT, sigmoidoscopy, or colonoscopy.

Scientists at Northwestern University (Chicago, IL, USA) conducted an outreach intervention program especially designed to patients who were overdue for colorectal cancer screening and were receiving care at a community health center that serves a primarily low-income population with a high proportion of immigrants and refugees. More...
The patients were sent an FOBT kit with instructions on how to use it.

A total of 317 patients aged 50 to 80 years had at least two visits to the study site between July 1, 2008, and December 31, 2009, and were eligible for the colorectal cancer screening measure. In all, 98 patients were randomized to the usual care group and 104 were randomized to the outreach intervention. The patients were racially and ethnically diverse, more than one-half of patients were women, and the vast majority was uninsured or publicly insured.

The main outcome of the study was 30% of patients assigned to the outreach intervention and 5% of patients assigned to the usual care group completed colorectal cancer screening between January 1, 2010, and June 30, 2010. Almost all of the completed colorectal cancer screening tests were the three-sample guaiac-based FOBT, the Hemoccult II SENSA Elite kits (Beckman Coulter, Brea, CA, USA).

The authors concluded that the direct-to-patient outreach intervention was effective even in a health care setting that had already implemented point-of-care clinician-directed electronic clinical reminders to promote appropriate colorectal cancer screening. This finding is especially important given the marked disparities in colorectal screening among racial and ethnic minorities, individuals with lower income and educational attainment, the uninsured, and individuals born outside the USA. The study was published in the September/October 2012 issue of the Annals of Family Medicine.

Related Links:

Northwestern University

Beckman Coulter




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.